Pulmonary Vascular Endothelial Cells in Lung Diseases: Mechanisms, Therapeutic Strategies, and Future Directions

Abstract

Pulmonary vascular endothelial cells (VECs) are essential for the normal function of the lung, through maintaining vascular barrier integrity, regulating blood flow, and participating in inflammatory responses to safeguard oxygen exchange and physiological homeostasis. The occurrence and development of various pulmonary diseases all take the injury of pulmonary VECs as an important pathological hub, which directly affects the therapeutic effect and prognosis recovery of patients. The injury mechanisms of pulmonary VECs present multi-dimensional network characteristics, involving inflammation and oxidative stress, genetic factors, cellular senescence, metabolic abnormalities, and immune dysregulation. Due to the unique physiological structure of the lungs, traditional drugs often encounter significant challenges in clinical application such as insufficient targeting, low bioavailability, and systemic side effects. In order to overcome the existing treatment bottlenecks, it is crucial to implement an in-depth analysis of the molecular mechanism of pulmonary VECs injury. This review systematically explores the mechanisms of pulmonary VECs injury, evaluates novel therapeutic strategies targeting pulmonary VECs' dysfunction, and discusses the challenges and future prospects of clinical translation. The goal is to shift pulmonary diseases treatment from symptom management to precise molecular intervention.

Keywords

anti-aging therapy / genetic therapy / immunomodulation / metabolic homeostasis / pulmonary diseases / vascular endothelial cells

References

[1] D. M. G. Halpin, “Mortality of Patients With COPD,” Expert Review of Respiratory Medicine 18, no. 6 (2024): 381–395.

[2] I. Borek, A. Birnhuber, N. F. Voelkel, L. M. Marsh, and G. Kwapiszewska, “The Vascular Perspective on Acute and Chronic Lung Disease,” Journal of Clinical Investigation 133, no. 16 (2023): e170502.

[3] X. Qi, Y. Luo, M. Xiao, et al., “Mechanisms of Alveolar Type 2 Epithelial Cell Death During Acute Lung Injury,” Stem Cells 41, no. 12 (2023): 1113–1132.

[4] W. Sun, W. Wu, X. Fang, et al., “Disruption of Pulmonary Microvascular Endothelial Barrier by Dysregulated Claudin-8 and Claudin-4: Uncovered Mechanisms in Porcine Reproductive and Respiratory Syndrome Virus Infection,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 240.

[5] L. Ma, Y. Wang, X. Li, et al., “Tom70-Regulated Mitochondrial Biogenesis via TFAM Improves Hypoxia-Induced Dysfunction of Pulmonary Vascular Endothelial Cells and Alleviates Hypoxic Pulmonary Hypertension,” Respiratory Research 24, no. 1 (2023): 310.

[6] S. Liu, Y. Zhao, H. Yao, et al., “DRP1 Knockdown and Atorvastatin Alleviate Ox-LDL-Induced Vascular Endothelial Cells Injury: DRP1 Is a Potential Target for Preventing Atherosclerosis,” Experimental Cell Research 429, no. 2 (2023): 113688.

[7] R. Franco and J. A. Cidlowski, “Apoptosis and Glutathione: Beyond an Antioxidant,” Cell Death and Differentiation 16, no. 10 (2009): 1303–1314.

[8] N. C. Huynh, T. T. T. Nguyen, D. T. C. Nguyen, and T. V. Tran, “Occurrence, Toxicity, Impact and Removal of Selected Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): A Review,” Science of the Total Environment 898 (2023): 165317.

[9] A. S. Yehualashet and T. F. Belachew, “ACEIs and ARBs and Their Correlation With COVID-19: A Review,” Infection and Drug Resistance 13 (2020): 3217–3224.

[10] M. Kolb, B. Crestani, and T. M. Maher, “Phosphodiesterase 4B Inhibition: A Potential Novel Strategy for Treating Pulmonary Fibrosis,” European Respiratory Review 32, no. 167 (2023): 220206.

[11] C. C. Hsu and M. P. Ho, “High-Dose Nitroglycerin Infusion for Acute Pulmonary Edema,” American Journal of Emergency Medicine 67 (2023): 178.

[12] S. Li, J. Zhang, X. Wang, et al., “Super-Enhancer Target Gene CBP/p300-Interacting Transactivator With Glu/Asp-Rich C-Terminal Domain, 2 Cooperates With Transcription Factor Forkhead Box J3 to Inhibit Pulmonary Vascular Remodeling,” Cell Proliferation 58, no. 11 (2025): e13817, https://doi.org/10.1111/cpr.13817.

[13] W. Jin, L. Liao, T. Qin, et al., “Recent Advances in Nanomedicine Therapy for Bacterial Pneumonia,” Chinese Chemical Letters 36, no. 6 (2025): 110920.

[14] J. C. Grotberg, D. Reynolds, and B. D. Kraft, “Management of Severe Acute Respiratory Distress Syndrome: A Primer,” Critical Care 27, no. 1 (2023): 289.

[15] R. Pofi, G. Caratti, D. W. Ray, and J. W. Tomlinson, “Treating the Side Effects of Exogenous Glucocorticoids; Can we Separate the Good From the Bad?,” Endocrine Reviews 44, no. 6 (2023): 975–1011.

[16] B. Tang, L. Xie, Y. Wang, et al., “Exploratory Research on the Effective Chemical Basis of Tanreqing Injection for Treating Acute Lung Injury: In Vivo, In Vitro and in Silico,” Journal of Ethnopharmacology 337 (2025): 118780.

[17] Y. X. Li, H. B. Wang, J. Li, J. B. Jin, J. B. Hu, and C. L. Yang, “Targeting Pulmonary Vascular Endothelial Cells for the Treatment of Respiratory Diseases,” Frontiers in Pharmacology 13 (2022): 983816.

[18] M. Ackermann, C. Werlein, E. Plucinski, et al., “The Role of Vasculature and Angiogenesis in Respiratory Diseases,” Angiogenesis 27, no. 3 (2024): 293–310.

[19] Y. H. Shen, D. Ding, T. Y. Lian, et al., “Panorama of Artery Endothelial Cell Dysfunction in Pulmonary Arterial Hypertension,” Journal of Molecular and Cellular Cardiology 197 (2024): 61–77.

[20] X. Qiao, J. Yin, Z. Zheng, L. Li, and X. Feng, “Endothelial Cell Dynamics in Sepsis-Induced Acute Lung Injury and Acute Respiratory Distress Syndrome: Pathogenesis and Therapeutic Implications,” Cell Communication and Signaling: CCS 22, no. 1 (2024): 241.

[21] J. Xu, Q. Zeng, S. Li, Q. Su, and H. Fan, “Inflammation Mechanism and Research Progress of COPD,” Frontiers in Immunology 15 (2024): 1404615.

[22] T. Koudstaal, M. Funke-Chambour, M. Kreuter, P. L. Molyneaux, and M. S. Wijsenbeek, “Pulmonary Fibrosis: From Pathogenesis to Clinical Decision-Making,” Trends in Molecular Medicine 29, no. 12 (2023): 1076–1087.

[23] J. Villar, T. Szakmany, G. Grasselli, and L. Camporota, “Redefining ARDS: A Paradigm Shift,” Critical Care 27, no. 1 (2023): 416.

[24] R. Diwan, H. N. Bhatt, E. Beaven, and M. Nurunnabi, “Emerging Delivery Approaches for Targeted Pulmonary Fibrosis Treatment,” Advanced Drug Delivery Reviews 204 (2024): 115147.

[25] A. Stierschneider and C. Wiesner, “Shedding Light on the Molecular and Regulatory Mechanisms of TLR4 Signaling in Endothelial Cells Under Physiological and Inflamed Conditions,” Frontiers in Immunology 14 (2023): 1264889.

[26] S. K. Kuss-Duerkop and A. M. Keestra-Gounder, “NOD1 and NOD2 Activation by Diverse Stimuli: A Possible Role for Sensing Pathogen-Induced Endoplasmic Reticulum Stress,” Infection and Immunity 88, no. 7 (2020): e00898-19.

[27] A. Ahmadi, S. Ahrari, J. Salimian, et al., “p38 MAPK Signaling in Chronic Obstructive Pulmonary Disease Pathogenesis and Inhibitor Therapeutics,” Cell Communication and Signaling: CCS 21, no. 1 (2023): 314.

[28] J. Wang, L. L. Li, Z. A. Zhao, C. Y. Niu, and Z. G. Zhao, “NLRP3 Inflammasome-Mediated Pyroptosis in Acute Lung Injury: Roles of Main Lung Cell Types and Therapeutic Perspectives,” International Immunopharmacology 154 (2025): 114560.

[29] Y. Chen, Y. Zhang, N. Li, Z. Jiang, and X. Li, “Role of Mitochondrial Stress and the NLRP3 Inflammasome in Lung Diseases,” Inflammation Research 72, no. 4 (2023): 829–846.

[30] C. Zhao, F. Liang, M. Ye, et al., “GSDMD Promotes Neutrophil Extracellular Traps via mtDNA-cGAS-STING Pathway During Lung Ischemia/Reperfusion,” Cell Death Discovery 9, no. 1 (2023): 368.

[31] S. Zhu, Y. Yu, M. Qu, et al., “Neutrophil Extracellular Traps Contribute to Immunothrombosis Formation via the STING Pathway in Sepsis-Associated Lung Injury,” Cell Death Discovery 9, no. 1 (2023): 315.

[32] A. Gorelova, M. Berman, and I. Al Ghouleh, “Endothelial-To-Mesenchymal Transition in Pulmonary Arterial Hypertension,” Antioxidants & Redox Signaling 34, no. 12 (2021): 891–914.

[33] A. V. Gaikwad, W. Lu, S. Dey, et al., “Endothelial-To-Mesenchymal Transition: A Precursor to Pulmonary Arterial Remodelling in Patients With Idiopathic Pulmonary Fibrosis,” ERJ Open Research 9, no. 2 (2023): 487–2022.

[34] P. Bhattarai, W. Lu, A. Hardikar, et al., “TGFβ1, SMAD and β-Catenin in Pulmonary Arteries of Smokers, Patients With Small Airway Disease and COPD: Potential Drivers of EndMT,” Clinical Science 138, no. 17 (2024): 1055–1070.

[35] H. Li, S. Zhang, X. Huang, et al., “Genetic Recording of Transient Endothelial Activation in Distinct Alveolar Capillary Cells During Pulmonary Fibrosis,” Cell Discovery 10, no. 1 (2024): 119.

[36] X. Wu, B. Wang, Y. Li, et al., “NIR Driven Catalytic Enhanced Acute Lung Injury Therapy by Using Polydopamine@co Nanozyme via Scavenging ROS,” Chinese Chemical Letters 36, no. 2 (2025): 110211.

[37] R. Damico, J. J. Zulueta, and P. M. Hassoun, “Pulmonary Endothelial Cell NOX,” American Journal of Respiratory Cell and Molecular Biology 47, no. 2 (2012): 129–139.

[38] D. Kračun, L. R. Lopes, E. Cifuentes-Pagano, and P. J. Pagano, “NADPH Oxidases: Redox Regulation of Cell Homeostasis and Disease,” Physiological Reviews 105, no. 3 (2025): 1291–1428.

[39] H. Yan, Y. Yin, Y. Zhou, et al., “Regulation of Cardiovascular Diseases by Histone Deacetylases and NADPH Oxidases,” Redox Biology 77 (2024): 103379.

[40] C. J. Goossen, A. Kufner, C. M. Dustin, et al., “Redox Regulation of Lung Endothelial PERK, Unfolded Protein Response (UPR) and Proliferation via NOX1: Targeted Inhibition as a Potential Therapy for PAH,” Redox Biology 82 (2025): 103554.

[41] S. M. H. Chan, K. Brassington, S. A. Almerdasi, et al., “Inhibition of Oxidative Stress by Apocynin Attenuated Chronic Obstructive Pulmonary Disease Progression and Vascular Injury by Cigarette Smoke Exposure,” British Journal of Pharmacology 180, no. 15 (2023): 2018–2034.

[42] D. S. Kostyunina, S. C. Rowan, N. V. Pakhomov, et al., “Shear Stress Markedly Alters the Proteomic Response to Hypoxia in Human Pulmonary Endothelial Cells,” American Journal of Respiratory Cell and Molecular Biology 68, no. 5 (2023): 551–565.

[43] M. W. Millar, R. A. Najar, S. A. Slavin, et al., “MTOR Maintains Endothelial Cell Integrity to Limit Lung Vascular Injury,” Journal of Biological Chemistry 300, no. 12 (2024): 107952.

[44] M. D. Li, L. Fu, B. B. Lv, et al., “Arsenic Induces Ferroptosis and Acute Lung Injury Through mtROS-Mediated Mitochondria-Associated Endoplasmic Reticulum Membrane Dysfunction,” Ecotoxicology and Environmental Safety 238 (2022): 113595.

[45] X. Cui, Y. Zhang, Y. Lu, and M. Xiang, “ROS and Endoplasmic Reticulum Stress in Pulmonary Disease,” Frontiers in Pharmacology 13 (2022): 879204.

[46] S. Wang, L. Hu, Y. Fu, et al., “Inhibition of IRE1α/XBP1 Axis Alleviates LPS-Induced Acute Lung Injury by Suppressing TXNIP/NLRP3 Inflammasome Activation and ERK/p65 Signaling Pathway,” Respiratory Research 25, no. 1 (2024): 417.

[47] Z. Sun, W. He, H. Meng, P. Li, and J. Qu, “Endoplasmic Reticulum Stress in Acute Lung Injury and Pulmonary Fibrosis,” FASEB Journal 38, no. 23 (2024): e70232.

[48] P. Keramidas, M. Pitou, E. Papachristou, and T. Choli-Papadopoulou, “Insights Into the Activation of Unfolded Protein Response Mechanism During Coronavirus Infection,” Current Issues in Molecular Biology 46, no. 5 (2024): 4286–4308.

[49] M. H. Cho, B. D. Hobbs, and E. K. Silverman, “Genetics of Chronic Obstructive Pulmonary Disease: Understanding the Pathobiology and Heterogeneity of a Complex Disorder,” Lancet Respiratory Medicine 10, no. 5 (2022): 485–496.

[50] G. Cerro Chiang and T. Parimon, “Understanding Interstitial Lung Diseases Associated With Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers,” International Journal of Molecular Sciences 24, no. 3 (2023): 2405.

[51] J. Feng, Y. Liu, K. Li, and Y. Wu, “Challenges and Opportunities in Targeting Epigenetic Mechanisms for Pulmonary Arterial Hypertension Treatment,” International Journal of Pharmaceutics 672 (2025): 125332.

[52] W. Lv, X. Gu, L. Zeng, et al., “Endothelial SMAD4 Deficiency Promotes Pulmonary Hypertension by Impairing Cell Adhesion and Extracellular Matrix Organization,” Hypertension 82, no. 7 (2025): 1175–1191.

[53] H. L. Ribeuz, A. S. Willer, B. Chevalier, et al., “Role of KCNK3 Dysfunction in Dasatinib-Associated Pulmonary Arterial Hypertension and Endothelial Cell Dysfunction,” American Journal of Respiratory Cell and Molecular Biology 71, no. 1 (2024): 95–109.

[54] B. Piper, S. Bogamuwa, T. Hossain, et al., “RAB7 Deficiency Impairs Pulmonary Artery Endothelial Function and Promotes Pulmonary Hypertension,” Journal of Clinical Investigation 134, no. 3 (2024): e169441.

[55] J. Ding, H. Jiang, B. Su, et al., “DNMT1/miR-130a/ZEB1 Regulatory Pathway Affects the Inflammatory Response in Lipopolysaccharide-Induced Sepsis,” DNA and Cell Biology 41, no. 5 (2022): 479–486.

[56] X. Huang, Z. Li, L. Zhang, et al., “miR-205-5p Inhibits Homocysteine-Induced Pulmonary Microvascular Endothelium Dysfunction by Targeting FOXO1,” Acta Biochimica et Biophysica Sinica 55, no. 9 (2023): 1456–1466.

[57] B. Bhargavan, B. Chhunchha, E. Kubo, and D. P. Singh, “DNA Methylation as an Epigenetic Mechanism in the Regulation of LEDGF Expression and Biological Response in Aging and Oxidative Stress,” Cell Death Discovery 10, no. 1 (2024): 296.

[58] J. Chen, J. Zhang, J. Wu, et al., “Low Shear Stress Induced Vascular Endothelial Cell Pyroptosis by TET2/SDHB/ROS Pathway,” Free Radical Biology & Medicine 162 (2021): 582–591.

[59] V. Singh and S. Ubaid, “Role of Silent Information Regulator 1 (SIRT1) in Regulating Oxidative Stress and Inflammation,” Inflammation 43, no. 5 (2020): 1589–1598.

[60] P. F. L. da Silva and B. Schumacher, “Principles of the Molecular and Cellular Mechanisms of Aging,” Journal of Investigative Dermatology 141, no. 4 (2021): 951–960.

[61] S. M. Lin and D. B. Frank, “SOX17 at the Intersection of Sex, Transcription, and Metabolism in Pulmonary Hypertension,” American Journal of Respiratory and Critical Care Medicine 207, no. 8 (2023): 971–972.

[62] R. Walters, E. Vasilaki, J. Aman, et al., “SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension,” Circulation 147, no. 21 (2023): 1606–1621.

[63] M. V. Holmes, C. Kartsonaki, R. Boxall, et al., “PCSK9 Genetic Variants and Risk of Vascular and Non-Vascular Diseases in Chinese and UK Populations,” European Journal of Preventive Cardiology 31, no. 8 (2024): 1015–1025.

[64] S. Cao, H. Li, J. Xin, et al., “Identification of Genetic Profile and Biomarkers Involved in Acute Respiratory Distress Syndrome,” Intensive Care Medicine 50, no. 1 (2024): 46–55.

[65] Z. Su, H. Su, J. Xu, et al., “Histone Methyltransferase Smyd2 Drives Vascular Aging by Its Enhancer-Dependent Activity,” Aging 15, no. 1 (2022): 70–91.

[66] L. Zhang, L. E. Pitcher, M. J. Yousefzadeh, L. J. Niedernhofer, P. D. Robbins, and Y. Zhu, “Cellular Senescence: A Key Therapeutic Target in Aging and Diseases,” Journal of Clinical Investigation 132, no. 15 (2022): e158450.

[67] B. L. Torrance and L. Haynes, “Cellular Senescence Is a Key Mediator of Lung Aging and Susceptibility to Infection,” Frontiers in Immunology 13 (2022): 1006710.

[68] B. J. Moss, S. W. Ryter, and I. O. Rosas, “Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis,” Annual Review of Pathology 17 (2022): 515–546.

[69] E. Safaie Qamsari and D. J. Stewart, “Cellular Senescence in the Pathogenesis of Pulmonary Arterial Hypertension: the Good, the Bad and the Uncertain,” Frontiers in Immunology 15 (2024): 1403669.

[70] Y. Zhao, M. Simon, A. Seluanov, and V. Gorbunova, “DNA Damage and Repair in Age-Related Inflammation,” Nature Reviews. Immunology 23, no. 2 (2023): 75–89.

[71] Y. Cheng, S. Wang, H. Zhang, et al., “A Non-Canonical Role for a Small Nucleolar RNA in Ribosome Biogenesis and Senescence,” Cell 187, no. 17 (2024): 4770–4789.

[72] J. Blázquez-Prieto, C. Huidobro, I. López-Alonso, et al., “Activation of p21 Limits Acute Lung Injury and Induces Early Senescence After Acid Aspiration and Mechanical Ventilation,” Translational Research 233 (2021): 104–116.

[73] M. Armanios, “The Role of Telomeres in Human Disease,” Annual Review of Genomics and Human Genetics 23 (2022): 363–381.

[74] P. Liao, B. Yan, C. Wang, and P. Lei, “Telomeres: Dysfunction, Maintenance, Aging and Cancer,” Aging and Disease 15, no. 6 (2023): 2595–2631.

[75] Z. Wu, J. Qu, and G. H. Liu, “Roles of Chromatin and Genome Instability in Cellular Senescence and Their Relevance to Ageing and Related Diseases,” Nature Reviews. Molecular Cell Biology 25, no. 12 (2024): 979–1000.

[76] E. Boniewska-Bernacka, A. Pańczyszyn, and M. Klinger, “Telomeres and Telomerase in Risk Assessment of Cardiovascular Diseases,” Experimental Cell Research 397, no. 2 (2020): 112361.

[77] S. I. Bloom, M. T. Islam, L. A. Lesniewski, and A. J. Donato, “Mechanisms and Consequences of Endothelial Cell Senescence,” Nature Reviews. Cardiology 20, no. 1 (2023): 38–51.

[78] J. Lin and E. Epel, “Stress and Telomere Shortening: Insights From Cellular Mechanisms,” Ageing Research Reviews 73 (2022): 101507.

[79] H. Guo, R. Yu, H. Zhang, and W. Wang, “Cytokine, Chemokine Alterations and Immune Cell Infiltration in Radiation-Induced Lung Injury: Implications for Prevention and Management,” International Immunopharmacology 126 (2024): 111263.

[80] H. J. Kim, W. J. Kim, H. R. Shin, et al., “ROS-Induced PADI2 Downregulation Accelerates Cellular Senescence via the Stimulation of SASP Production and NFκB Activation,” Cellular and Molecular Life Sciences 79, no. 3 (2022): 155.

[81] C. Araki, D. Takemoto, Y. Kitagawa, et al., “Sesamin Metabolites Suppress the Induction of Cellular Senescence,” Nutrients 15, no. 7 (2023): 1627.

[82] L. Liu, Y. Wei, S. Giunta, Q. He, and S. Xia, “Potential Role of Cellular Senescence in Pulmonary Arterial Hypertension,” Clinical and Experimental Pharmacology & Physiology 49, no. 10 (2022): 1042–1049.

[83] A. A. Raslan, T. X. Pham, J. Lee, et al., “Lung Injury-Induced Activated Endothelial Cell States Persist in Aging-Associated Progressive Fibrosis,” Nature Communications 15, no. 1 (2024): 5449.

[84] B. Wang, J. Han, J. H. Elisseeff, and M. Demaria, “The Senescence-Associated Secretory Phenotype and Its Physiological and Pathological Implications,” Nature Reviews. Molecular Cell Biology 25, no. 12 (2024): 958–978.

[85] S. M. Lagoumtzi and N. Chondrogianni, “Senolytics and Senomorphics: Natural and Synthetic Therapeutics in the Treatment of Aging and Chronic Diseases,” Free Radical Biology & Medicine 171 (2021): 169–190.

[86] I. Roger, J. Milara, N. Belhadj, and J. Cortijo, “Senescence Alterations in Pulmonary Hypertension,” Cells 10, no. 12 (2021): 3456.

[87] S. Subedi, M. Guntipally, N. Suwal, et al., “Cellular Senescence in Chronic Obstructive Pulmonary Disease: Molecular Mechanisms and Therapeutic Interventions,” Ageing Research Reviews 110 (2025): 102813.

[88] R. P. Stevens, S. S. Paudel, S. C. Johnson, T. Stevens, and J. Y. Lee, “Endothelial Metabolism in Pulmonary Vascular Homeostasis and Acute Respiratory Distress Syndrome,” American Journal of Physiology. Lung Cellular and Molecular Physiology 321, no. 2 (2021): L358–L376.

[89] S. J. Kierans and C. T. Taylor, “Regulation of Glycolysis by the Hypoxia-Inducible Factor (HIF): Implications for Cellular Physiology,” Journal of Physiology 599, no. 1 (2021): 23–37.

[90] M. Tian, W. Liu, X. Li, et al., “HIF-1α Promotes SARS-CoV-2 Infection and Aggravates Inflammatory Responses to COVID-19,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 308.

[91] N. Moasefi, M. Fouladi, A. H. Norooznezhad, R. Yarani, A. Rahmani, and K. Mansouri, “How Could Perfluorocarbon Affect Cytokine Storm and Angiogenesis in Coronavirus Disease 2019 (COVID-19): Role of Hypoxia-Inducible Factor 1α,” Inflammation Research 70, no. 7 (2021): 749–752.

[92] X. Zhang, J. Li, M. Fu, et al., “Dysfunction in Mitochondrial Electron Transport Chain Drives the Pathogenesis of Pulmonary Arterial Hypertension: Insights From a Multi-Omics Investigation,” Respiratory Research 26, no. 1 (2025): 29.

[93] Y. Zhang, J. Wang, M. He, et al., “Hypobaric Hypoxia-Driven Energy Metabolism Disturbance Facilitates Vascular Endothelial Dysfunction,” Redox Biology 84 (2025): 103675.

[94] Y. Shi, J. Liu, R. Zhang, et al., “Targeting Endothelial ENO1 (Alpha-Enolase) -PI3K-Akt-mTOR Axis Alleviates Hypoxic Pulmonary Hypertension,” Hypertension 80, no. 5 (2023): 1035–1047.

[95] M. Truchi, M. Gautier-Isola, G. Savary, et al., “Aging Affects Reprogramming of Pulmonary Capillary Endothelial Cells After Lung Injury in Male Mice,” Nature Communications 16, no. 1 (2025): 7234.

[96] L. K. Stabenow, D. Zibrova, C. Ender, et al., “Oxidative Glucose Metabolism Promotes Senescence in Vascular Endothelial Cells,” Cells 11, no. 14 (2022): 2213.

[97] X. Shi, Y. Chen, M. Shi, et al., “The Novel Molecular Mechanism of Pulmonary Fibrosis: Insight Into Lipid Metabolism From Reanalysis of Single-Cell RNA-Seq Databases,” Lipids in Health and Disease 23, no. 1 (2024): 98.

[98] Y. T. Wang, A. K. Moura, R. Zuo, et al., “Defective Lipid Droplet Biogenesis Exacerbates Oleic Acid-Induced Cellular Homeostasis Disruption and Ferroptosis in Mouse Cardiac Endothelial Cells,” Cell Death Discovery 11, no. 1 (2025): 374.

[99] Y. Shimizu, Y. Horibata, M. Domae, et al., “Dysregulated Metabolic Pathways of Pulmonary Fibrosis and the Lipids Associated With the Effects of Nintedanib Therapy,” Respiratory Research 26, no. 1 (2025): 166.

[100] M. D. Pokharel, D. P. Marciano, P. Fu, et al., “Metabolic Reprogramming, Oxidative Stress, and Pulmonary Hypertension,” Redox Biology 64 (2023): 102797.

[101] S. Hu, X. Zhao, R. Li, et al., “Activating Transcription Factor 3, Glucolipid Metabolism, and Metabolic Diseases,” Journal of Molecular Cell Biology 14, no. 10 (2023): mjac067.

[102] Q. Tu, Y. Li, J. Zhu, et al., “Mitochondrial DNA Mediates Immunoparalysis of Dendritic Cells in Sepsis via STING Signalling,” Cell Proliferation 55, no. 12 (2022): e13328.

[103] R. Gupta, M. Kanai, T. J. Durham, et al., “Nuclear Genetic Control of mtDNA Copy Number and Heteroplasmy in Humans,” Nature 620, no. 7975 (2023): 839–848.

[104] Y. Liu, Y. Huang, C. Xu, et al., “Mitochondrial Dysfunction and Therapeutic Perspectives in Cardiovascular Diseases,” International Journal of Molecular Sciences 23, no. 24 (2022): 16053.

[105] Y. Feng, P. Yuan, H. Guo, et al., “METTL3 Mediates Epithelial-Mesenchymal Transition by Modulating FOXO1 mRNA N(6) -Methyladenosine-Dependent YTHDF2 Binding: A Novel Mechanism of Radiation-Induced Lung Injury,” Advancement of Science 10, no. 17 (2023): e2204784.

[106] L. Neyton and C. S. Calfee, “Metabolic Signatures of ARDS and ARDS Heterogeneity,” American Journal of Physiology. Lung Cellular and Molecular Physiology 321, no. 6 (2021): L1067–L1068.

[107] S. Dubey, Z. Yu, E. M. Stephens, et al., “Oxidative Damage to Lung Mitochondrial DNA Is a Key Contributor to the Development of Chemical Lung Injury,” Redox Biology 82 (2025): 103624.

[108] J. Zhang, J. Du, D. Liu, et al., “Polystyrene Microplastics Induce Pulmonary Fibrosis by Promoting Alveolar Epithelial Cell Ferroptosis Through cGAS/STING Signaling,” Ecotoxicology and Environmental Safety 277 (2024): 116357.

[109] S. A. Ware, C. R. Kliment, L. Giordano, et al., “Cell-Free DNA Levels Associate With COPD Exacerbations and Mortality,” Respiratory Research 25, no. 1 (2024): 42.

[110] D. Kumari, Y. Singh, S. Singh, et al., “Mitochondrial Pathogenic Mutations and Metabolic Alterations Associated With COVID-19 Disease Severity,” Journal of Medical Virology 95, no. 2 (2023): e28553.

[111] S. L. Archer, A. Dasgupta, K. H. Chen, et al., “SARS-CoV-2 Mitochondriopathy in COVID-19 Pneumonia Exacerbates Hypoxemia,” Redox Biology 58 (2022): 102508.

[112] N. M. Breault, D. Wu, A. Dasgupta, K. H. Chen, and S. L. Archer, “Acquired Disorders of Mitochondrial Metabolism and Dynamics in Pulmonary Arterial Hypertension,” Frontiers in Cell and Developmental Biology 11 (2023): 1105565.

[113] Y. Pei, D. Ren, Y. Yin, et al., “Endothelial FUNDC1 Deficiency Drives Pulmonary Hypertension,” Circulation Research 136, no. 2 (2025): e1–e19.

[114] X. Li, P. Hou, W. Ma, et al., “Author Correction: SARS-CoV-2 ORF10 Suppresses the Antiviral Innate Immune Response by Degrading MAVS Through Mitophagy,” Cellular & Molecular Immunology 20, no. 6 (2023): 686.

[115] J. Le, Y. Kulatheepan, and S. Jeyaseelan, “Role of Toll-Like Receptors and Nod-Like Receptors in Acute Lung Infection,” Frontiers in Immunology 14 (2023): 1249098.

[116] J. B. Xu, W. J. Guan, Y. L. Zhang, et al., “SARS-CoV-2 Envelope Protein Impairs Airway Epithelial Barrier Function and Exacerbates Airway Inflammation via Increased Intracellular cl(−) Concentration,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 74.

[117] H. X. Yuan, Y. T. Chen, Y. Q. Li, et al., “Endothelial Extracellular Vesicles Induce Acute Lung Injury via Follistatin-Like Protein 1,” Science China. Life Sciences 67, no. 3 (2024): 475–487.

[118] L. Ji, S. Su, M. Xin, et al., “Luteolin Ameliorates Hypoxia-Induced Pulmonary Hypertension via Regulating HIF-2α-Arg-NO Axis and PI3K-AKT-eNOS-NO Signaling Pathway,” Phytomedicine 104 (2022): 154329.

[119] D. M. Kim, Y. Kim, J. W. Seo, et al., “Enhanced Eosinophil-Mediated Inflammation Associated With Antibody and Complement-Dependent Pneumonic Insults in Critical COVID-19,” Cell Reports 37, no. 1 (2021): 109798.

[120] E. Azoulay, J. Zuber, A. A. Bousfiha, et al., “Complement System Activation: Bridging Physiology, Pathophysiology, and Therapy,” Intensive Care Medicine 50, no. 11 (2024): 1791–1803.

[121] S. J. Cleary, Y. Seo, J. J. Tian, et al., “IgG Hexamers Initiate Complement-Dependent Acute Lung Injury,” Journal of Clinical Investigation 134, no. 11 (2024): e178351.

[122] M. Ackermann, S. E. Verleden, M. Kuehnel, et al., “Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19,” New England Journal of Medicine 383, no. 2 (2020): 120–128.

[123] M. G. Detsika, K. Palamaris, I. Dimopoulou, A. Kotanidou, and S. E. Orfanos, “The Complement Cascade in Lung Injury and Disease,” Respiratory Research 25, no. 1 (2024): 20.

[124] S. Grumelli, B. Lu, L. Peterson, T. Maeno, and C. Gerard, “CD46 Protects Against Chronic Obstructive Pulmonary Disease,” PLoS One 6, no. 5 (2011): e18785.

[125] F. Ding, M. Zhou, Y. Ren, et al., “Mitochondrial Extracellular Vesicles: A Promising Avenue for Diagnosing and Treating Lung Diseases,” ACS Nano 18, no. 37 (2024): 25372–25404.

[126] E. I. Buzas, “The Roles of Extracellular Vesicles in the Immune System,” Nature Reviews. Immunology 23, no. 4 (2023): 236–250.

[127] R. Kalluri, “The Biology and Function of Extracellular Vesicles in Immune Response and Immunity,” Immunity 57, no. 8 (2024): 1752–1768.

[128] B. Krishnamachary, C. Cook, A. Kumar, L. Spikes, P. Chalise, and N. K. Dhillon, “Extracellular Vesicle-Mediated Endothelial Apoptosis and EV-Associated Proteins Correlate With COVID-19 Disease Severity,” Journal of Extracellular Vesicles 10, no. 9 (2021): e12117.

[129] J. C. Santos-Álvarez, J. M. Velázquez-Enríquez, R. García-Carrillo, et al., “miRNAs Contained in Extracellular Vesicles Cargo Contribute to the Progression of Idiopathic Pulmonary Fibrosis: An In Vitro Aproach,” Cells 11, no. 7 (2022): 1112.

[130] N. Gomez, V. James, D. Onion, and L. C. Fairclough, “Extracellular Vesicles and Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review,” Respiratory Research 23, no. 1 (2022): 82.

[131] S. Bartel, J. C. Wolters, H. Noor, et al., “Altered Extracellular Vesicle-Derived Protein and microRNA Signatures in Bronchoalveolar Lavage Fluid From Patients With Chronic Obstructive Pulmonary Disease,” Cells 13, no. 11 (2024): 945.

[132] Y. Ma, X. He, X. Liu, Y. Long, and Y. Chen, “Endothelial Microparticles Derived From Primary Pulmonary Microvascular Endothelial Cells Mediate Lung Inflammation in Chronic Obstructive Pulmonary Disease by Transferring microRNA-126,” Journal of Inflammation Research 15 (2022): 1399–1411.

[133] K. S. Park, C. Lässer, and J. Lötvall, “Extracellular Vesicles and the Lung: From Disease Pathogenesis to Biomarkers and Treatments,” Physiological Reviews 105, no. 3 (2025): 1733–1821.

[134] G. Song, S. Wang, M. N. Barkestani, et al., “Membrane Attack Complexes, Endothelial Cell Activation, and Direct Allorecognition,” Frontiers in Immunology 13 (2022): 1020889.

[135] S. R. Barnum, D. Bubeck, and T. N. Schein, “Soluble Membrane Attack Complex: Biochemistry and Immunobiology,” Frontiers in Immunology 11 (2020): 585108.

[136] I. Cavazzana, T. Vojinovic, P. Airo, et al., “Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers,” Clinical Reviews in Allergy & Immunology 64, no. 3 (2023): 412–430.

[137] N. W. Preite, B. M. Borges, V. L. Kaminski, et al., “Blocking the CTLA-4 and PD-1 Pathways During Pulmonary Paracoccidioidomycosis Improves Immunity, Reduces Disease Severity, and Increases the Survival of Infected Mice,” Frontiers in Immunology 15 (2024): 1347318.

[138] D. R. Beserra, R. W. Alberca, A. Branco, et al., “Upregulation of PD-1 Expression and High sPD-L1 Levels Associated With COVID-19 Severity,” Journal of Immunology Research 2022 (2022): 9764002.

[139] K. J. Mould and W. J. Janssen, “Balancing Act: PD-1, PD-L1, and the Inflammatory Tightrope of Acute Respiratory Distress Syndrome,” American Journal of Respiratory Cell and Molecular Biology 71, no. 5 (2024): 505–506.

[140] L. Wang, M. Mu, Y. Guo, et al., “PD-1/PD-L1 Provides Protective Role in Hypoxia-Induced Pulmonary Vascular Remodeling,” Hypertension 81, no. 8 (2024): 1822–1836.

[141] I. A. Savin, M. A. Zenkova, and A. V. Sen'kova, “Pulmonary Fibrosis as a Result of Acute Lung Inflammation: Molecular Mechanisms, Relevant In Vivo Models, Prognostic and Therapeutic Approaches,” International Journal of Molecular Sciences 23, no. 23 (2022): 14959.

[142] L. D. J. Bos and L. B. Ware, “Acute Respiratory Distress Syndrome: Causes, Pathophysiology, and Phenotypes,” Lancet 400, no. 10358 (2022): 1145–1156.

[143] J. Li, M. Hua, X. Hu, et al., “Dexamethasone Suppresses the Th17/1 Cell Polarization in the CD4(+) T Cells From Patients With Primary Immune Thrombocytopenia,” Thrombosis Research 190 (2020): 26–34.

[144] J. W. Yang, B. Mao, R. J. Tao, et al., “Corticosteroids Alleviate Lipopolysaccharide-Induced Inflammation and Lung Injury via Inhibiting NLRP3-Inflammasome Activation,” Journal of Cellular and Molecular Medicine 24, no. 21 (2020): 12716–12725.

[145] G. W. Williams, N. K. Berg, A. Reskallah, X. Yuan, and H. K. Eltzschig, “Acute Respiratory Distress Syndrome,” Anesthesiology 134, no. 2 (2021): 270–282.

[146] J. W. Kwon, H. Quan, J. Song, et al., “Liposomal Dexamethasone Reduces A/H1N1 Influenza-Associated Morbidity in Mice,” Frontiers in Microbiology 13 (2022): 845795.

[147] U. E. Ewii, A. L. Onugwu, V. C. Nwokpor, et al., “Novel Drug Delivery Systems: Insight Into Self-Powered and Nano-Enabled Drug Delivery Systems,” Nano TransMed 3 (2024): 100042.

[148] Y. X. Zhu, H. R. Jia, Y. W. Jiang, et al., “A Red Blood Cell-Derived Bionic Microrobot Capable of Hierarchically Adapting to Five Critical Stages in Systemic Drug Delivery,” Exploration 4, no. 2 (2023): 20230105.

[149] L. Ma, F. Chen, S. Chen, et al., “Inflammation-Targeting Nanoparticles Impede Neutrophil Infiltration and Scavenge ROS for Acute Lung Injury Alleviation,” International Journal of Pharmaceutics 673 (2025): 125359.

[150] C. H. Liu, P. R. Jheng, L. Rethi, et al., “P-Selectin Mediates Targeting of a Self-Assembling Phototherapeutic Nanovehicle Enclosing Dipyridamole for Managing Thromboses,” Journal of Nanobiotechnology 21, no. 1 (2023): 260.

[151] E. V. Fuior, C. A. Mocanu, M. Deleanu, et al., “Evaluation of VCAM-1 Targeted Naringenin/Indocyanine Green-Loaded Lipid Nanoemulsions as Theranostic Nanoplatforms in Inflammation,” Pharmaceutics 12, no. 11 (2020): 1066.

[152] M. Li, X. Shang, H. Lou, et al., “Active Anchoring Stimuli-Responsive Nano-Craft to Relieve Pulmonary Vasoconstriction by Targeting Smooth Muscle Cell for Hypoxic Pulmonary Hypertension Treatment,” Advanced Healthcare Materials 13, no. 15 (2024): e2400113.

[153] J. X. He, C. Q. Zhu, G. F. Liang, H. B. Mao, W. Y. Shen, and J. B. Hu, “Targeted-Lung Delivery of Bardoxolone Methyl Using PECAM-1 Antibody-Conjugated Nanostructure Lipid Carriers for the Treatment of Lung Inflammation,” Biomedicine & Pharmacotherapy 178 (2024): 116992.

[154] J. B. Jin, J. Li, H. B. Wang, J. B. Hu, and C. L. Yang, “Engineering of VCAM-1-Targeted Nanostructured Lipid Carriers for Delivery of Melatonin Against Acute Lung Injury Through SIRT1/NLRP3 Mediated Pyroptosis Signaling Pathway,” International Journal of Biological Macromolecules 266 (2024): 130637.

[155] S. Jiang, S. Li, J. Hu, et al., “Combined Delivery of Angiopoietin-1 Gene and Simvastatin Mediated by Anti-Intercellular Adhesion Molecule-1 Antibody-Conjugated Ternary Nanoparticles for Acute Lung Injury Therapy,” Nanomedicine 15, no. 1 (2019): 25–36.

[156] T. R. Nayak, A. Chrastina, J. Valencia, et al., “Rapid Precision Targeting of Nanoparticles to Lung via Caveolae Pumping System in Endothelium,” Nature Nanotechnology 20, no. 1 (2025): 144–155.

[157] J. H. Park, Y. Jiang, J. Zhou, et al., “Genetically Engineered Cell Membrane-Coated Nanoparticles for Targeted Delivery of Dexamethasone to Inflamed Lungs,” Science Advances 7, no. 25 (2021): eabf7820.

[158] W. Bai, S. Chen, T. Liu, et al., “Dual-Action Membrane-Chimeric Liposomes With Self-Reinforcing Targeting for Acute Lung Injury Treatment,” Journal of Controlled Release 383 (2025): 113820.

[159] Y. Yang, M. Zoulikha, Q. Xiao, et al., “Pulmonary Endothelium-Targeted Nanoassembly of Indomethacin and Superoxide Dismutase Relieves Lung Inflammation,” Acta Pharmaceutica Sinica B 13, no. 11 (2023): 4607–4620.

[160] M. Hassanpour, A. A. Salybkov, S. Kobayashi, and T. Asahara, “Anti-Inflammatory Prowess of Endothelial Progenitor Cells in the Realm of Biology and Medicine,” Npj Regenerative Medicine 9, no. 1 (2024): 27.

[161] F. Yan, X. Liu, H. Ding, and W. Zhang, “Paracrine Mechanisms of Endothelial Progenitor Cells in Vascular Repair,” Acta Histochemica 124, no. 1 (2022): 151833.

[162] S. Rashidi, G. Bagherpour, Z. Abbasi-Malati, et al., “Endothelial Progenitor Cells for Fabrication of Engineered Vascular Units and Angiogenesis Induction,” Cell Proliferation 57, no. 9 (2024): e13716.

[163] A. Bordin, M. Chirivì, F. Pagano, et al., “Human Platelet Lysate-Derived Extracellular Vesicles Enhance Angiogenesis Through miR-126,” Cell Proliferation 55, no. 11 (2022): e13312.

[164] F. Yan, J. Li, and W. Zhang, “Transplantation of Endothelial Progenitor Cells: Summary and Prospect,” Acta Histochemica 125, no. 1 (2023): 151990.

[165] M. Mao, L. Hao, Y. Wang, and Q. Q. Liu, “Transplantation of Endothelial Progenitor Cells Attenuates Lipopolysaccharide-Induced Lung Injury via Inhibiting the Inflammatory Secretion of Neutrophils in Rats,” American Journal of the Medical Sciences 357, no. 1 (2019): 49–56.

[166] Z. Li, S. Niu, B. Guo, et al., “Stem Cell Therapy for COVID-19, ARDS and Pulmonary Fibrosis,” Cell Proliferation 53, no. 12 (2020): e12939.

[167] J. Halliwell, I. Barbaric, and P. W. Andrews, “Acquired Genetic Changes in Human Pluripotent Stem Cells: Origins and Consequences,” Nature Reviews. Molecular Cell Biology 21, no. 12 (2020): 715–728.

[168] S. Ben Fraj, S. Naserian, B. Lorenzini, et al., “Human Umbilical Cord Blood Endothelial Progenitor Cell-Derived Extracellular Vesicles Control Important Endothelial Cell Functions,” International Journal of Molecular Sciences 24, no. 12 (2023): 9866.

[169] M. H. Azhdari, N. Goodarzi, M. Doroudian, and R. MacLoughlin, “Molecular Insight Into the Therapeutic Effects of Stem Cell-Derived Exosomes in Respiratory Diseases and the Potential for Pulmonary Delivery,” International Journal of Molecular Sciences 23, no. 11 (2022): 6273.

[170] G. Fu, Z. Wang, and S. Hu, “Exercise Improves Cardiac Fibrosis by Stimulating the Release of Endothelial Progenitor Cell-Derived Exosomes and Upregulating miR-126 Expression,” Frontiers in Cardiovascular Medicine 11 (2024): 1323329.

[171] L. Yang, T. Chen, Y. Huang, Y. Yang, X. Cheng, and F. Wei, “hnRNPA2B1 Promotes the Production of Exosomal miR-103-3p From Endothelial Progenitor Cells to Alleviate Macrophage M1 Polarization in Acute Respiratory Distress Syndrome,” International Immunopharmacology 158 (2025): 114830.

[172] D. X. Chen, C. H. Lu, N. Na, R. X. Yin, and F. Huang, “Endothelial Progenitor Cell-Derived Extracellular Vesicles: the World of Potential Prospects for the Treatment of Cardiovascular Diseases,” Cell & Bioscience 14, no. 1 (2024): 72.

[173] Y. Zhou, P. Li, A. J. Goodwin, et al., “Exosomes From Endothelial Progenitor Cells Improve the Outcome of a Murine Model of Sepsis,” Molecular Therapy 26, no. 5 (2018): 1375–1384.

[174] M. S. Yang, M. J. Park, J. Lee, et al., “Non-Invasive Administration of AAV to Target Lung Parenchymal Cells and Develop SARS-CoV-2-Susceptible Mice,” Molecular Therapy 30, no. 5 (2022): 1994–2004.

[175] A. M. Reynolds, M. D. Holmes, S. M. Danilov, and P. N. Reynolds, “Targeted Gene Delivery of BMPR2 Attenuates Pulmonary Hypertension,” European Respiratory Journal 39, no. 2 (2012): 329–343.

[176] M. Bisserier, P. Mathiyalagan, S. Zhang, et al., “Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension,” Circulation 144, no. 1 (2021): 52–73.

[177] Y. Cao, R. Wang, X. He, et al., “Targeted Delivery of BMPR2 mRNA Attenuates Pulmonary Arterial Hypertension by Reversing Pulmonary Vascular Remodeling,” Acta Pharmaceutica Sinica B 15 (2025): 5416–5430.

[178] Y. L. Wu, Z. J. Lin, C. C. Li, et al., “Epigenetic Regulation in Metabolic Diseases: Mechanisms and Advances in Clinical Study,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 98.

[179] Y. Lin, T. Qiu, G. Wei, et al., “Role of Histone Post-Translational Modifications in Inflammatory Diseases,” Frontiers in Immunology 13 (2022): 852272.

[180] S. Rath, Y. M. Hawsawi, F. Alzahrani, and M. I. Khan, “Epigenetic Regulation of Inflammation: The Metabolomics Connection,” Seminars in Cell & Developmental Biology 154 (2024): 355–363.

[181] J. Zhou, X. An, X. Xia, et al., “Aging-Associated Interleukin-11 Drives the Molecular Mechanism and Targeted Therapy of Idiopathic Pulmonary Fibrosis,” European Journal of Medical Research 30, no. 1 (2025): 542.

[182] K. Chen, H. Han, S. Zhao, et al., “Lung and Liver Editing by Lipid Nanoparticle Delivery of a Stable CRISPR-Cas9 Ribonucleoprotein,” Nature Biotechnology 43 (2025): 1445–1457.

[183] J. Dave, V. Jagana, R. Janostiak, and M. Bisserier, “Unraveling the Epigenetic Landscape of Pulmonary Arterial Hypertension: Implications for Personalized Medicine Development,” Journal of Translational Medicine 21, no. 1 (2023): 477.

[184] L. Tian, D. Wu, A. Dasgupta, et al., “Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension: A Pyruvate Dehydrogenase Kinase-Dependent Shift in Mitochondrial Metabolism Promotes Right Ventricular Fibrosis,” Circulation Research 126, no. 12 (2020): 1723–1745.

[185] T. J. Applegate, G. M. Krafsur, J. A. Boon, et al., “Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension,” Frontiers in Physiology 12 (2021): 712583.

[186] L. Yan, Y. Su, I. Hsia, et al., “Delivery of Anti-microRNA-21 by Lung-Targeted Liposomes for Pulmonary Fibrosis Treatment,” Molecular Therapy - Nucleic Acids 32 (2023): 36–47.

[187] S. I. Bloom, Y. Liu, J. R. Tucker, et al., “Endothelial Cell Telomere Dysfunction Induces Senescence and Results in Vascular and Metabolic Impairments,” Aging Cell 22, no. 8 (2023): e13875.

[188] S. I. Bloom, J. R. Tucker, Y. Liu, et al., “Aging Results in Endothelial Cell Telomere Uncapping That Induces Senescence and Physiological Dysfunction,” FASEB Journal 36, no. S1 (2022): R4606.

[189] F. Dogan and N. R. Forsyth, “TERT Promoter Methylation Is Oxygen-Sensitive and Regulates Telomerase Activity,” Biomolecules 14, no. 1 (2024): 131.

[190] A. Martin and D. Hockemeyer, “Regulation of Human Telomerase: From Molecular Interactions to Population Genetics,” Cold Spring Harbor Perspectives in Biology 17, no. 10 (2025): a041693.

[191] A. J. F. Tiendrébéogo, T. Soumagne, F. Pellegrin, et al., “The Telomerase Activator TA-65 Protects From Cigarette Smoke-Induced Small Airway Remodeling in Mice Through Extra-Telomeric Effects,” Scientific Reports 13, no. 1 (2023): 25.

[192] H. S. Shim, J. Iaconelli, X. Shang, et al., “TERT Activation Targets DNA Methylation and Multiple Aging Hallmarks,” Cell 187, no. 15 (2024): 4030–4042.

[193] M. Campisi, L. Cannella, O. Paccagnella, et al., “Unveiling the Geroprotective Potential of Monarda didyma L.: Insights From In Vitro Studies and a Randomized Clinical Trial on Slowing Biological Aging and Improving Quality of Life,” GeroScience 47, no. 3 (2025): 4253–4290.

[194] A. Nambiar, D. Kellogg, III, J. Justice, et al., “Senolytics Dasatinib and Quercetin in Idiopathic Pulmonary Fibrosis: Results of a Phase I, Single-Blind, Single-Center, Randomized, Placebo-Controlled Pilot Trial on Feasibility and Tolerability,” eBioMedicine 90 (2023): 104481.

[195] J. R. Baker, L. Daly, S. Hassibi, et al., “Senolytic Therapy Reduces Inflammation in Epithelial Cells From COPD Patients and in Smoke-Exposure Mice,” Frontiers in Medicine 12 (2025): 1451056.

[196] S. A. Mahoney, R. Venkatasubramanian, M. A. Darrah, et al., “Intermittent Supplementation With Fisetin Improves Arterial Function in Old Mice by Decreasing Cellular Senescence,” Aging Cell 23, no. 3 (2024): e14060.

[197] N. Martin, A. Huna, and D. Bernard, “Elimination of Senescent Endothelial Cells: Good or Bad Idea?,” Trends in Cell Biology 31, no. 5 (2021): 327–330.

[198] B. Liu and Z. Dai, “Fatty Acid Metabolism in Endothelial Cell,” Genes 13, no. 12 (2022): 2301.

[199] L. Zhou, J. Li, J. Wang, X. Niu, J. Li, and K. Zhang, “Pathogenic Role of PFKFB3 in Endothelial Inflammatory Diseases,” Frontiers in Molecular Biosciences 11 (2024): 1454456.

[200] H. Peng, X. Wang, J. Du, Q. Cui, Y. Huang, and H. Jin, “Metabolic Reprogramming of Vascular Endothelial Cells: Basic Research and Clinical Applications,” Frontiers in Cell and Development Biology 9 (2021): 626047.

[201] Q. D. Angeles-Lopez, J. Rodriguez-Lopez, P. Agudelo Garcia, et al., “Regulation of Lung Progenitor Plasticity and Repair by Fatty Acid Oxidation,” JCI Insight 10, no. 3 (2025): e165837.

[202] S. H. Moon, X. Liu, C. M. Jenkins, B. G. Dilthey, G. J. Patti, and R. W. Gross, “Etomoxir-Carnitine, a Novel Pharmaco-Metabolite of Etomoxir, Inhibits Phospholipases A(2) and Mitochondrial Respiration,” Journal of Lipid Research 65, no. 9 (2024): 100611.

[203] G. Y. Wang, X. Xu, D. Y. Xiong, L. Deng, W. Liu, and X. T. Huang, “CPT1A as a Potential Therapeutic Target for Lipopolysaccharide-Induced Acute Lung Injury in Mice,” Scientific Reports 14, no. 1 (2024): 1600.

[204] A. S. Monzel, J. A. Enríquez, and M. Picard, “Multifaceted Mitochondria: Moving Mitochondrial Science Beyond Function and Dysfunction,” Nature Metabolism 5, no. 4 (2023): 546–562.

[205] N. Borcherding and J. R. Brestoff, “The Power and Potential of Mitochondria Transfer,” Nature 623, no. 7986 (2023): 283–291.

[206] J. L. Gollihue, S. P. Patel, K. C. Eldahan, et al., “Effects of Mitochondrial Transplantation on Bioenergetics, Cellular Incorporation, and Functional Recovery After Spinal Cord Injury,” Journal of Neurotrauma 35, no. 15 (2018): 1800–1818.

[207] D. Valenti, R. A. Vacca, L. Moro, and A. Atlante, “Mitochondria Can Cross Cell Boundaries: An Overview of the Biological Relevance, Pathophysiological Implications and Therapeutic Perspectives of Intercellular Mitochondrial Transfer,” International Journal of Molecular Sciences 22, no. 15 (2021): 8312.

[208] C. M. Cloer, C. S. Givens, L. K. Buie, et al., “Mitochondrial Transplant After Ischemia Reperfusion Promotes Cellular Salvage and Improves Lung Function During Ex-Vivo Lung Perfusion,” Journal of Heart and Lung Transplantation 42, no. 5 (2023): 575–584.

[209] R. Z. Lin, G. B. Im, A. C. Luo, et al., “Mitochondrial Transfer Mediates Endothelial Cell Engraftment Through Mitophagy,” Nature 629, no. 8012 (2024): 660–668.

[210] J. M. Quiles and Å. B. Gustafsson, “The Role of Mitochondrial Fission in Cardiovascular Health and Disease,” Nature Reviews. Cardiology 19, no. 11 (2022): 723–736.

[211] M. Yegambaram, X. Sun, A. G. Flores, et al., “Novel Relationship Between Mitofusin 2-Mediated Mitochondrial Hyperfusion, Metabolic Remodeling, and Glycolysis in Pulmonary Arterial Endothelial Cells,” International Journal of Molecular Sciences 24, no. 24 (2023): 17533.

[212] M. Yegambaram, X. Sun, Q. Lu, et al., “Mitochondrial Hyperfusion Induces Metabolic Remodeling in Lung Endothelial Cells by Modifying the Activities of Electron Transport Chain Complexes I and III,” Free Radical Biology & Medicine 210 (2024): 183–194.

[213] P. Colpman, A. Dasgupta, and S. L. Archer, “The Role of Mitochondrial Dynamics and Mitotic Fission in Regulating the Cell Cycle in Cancer and Pulmonary Arterial Hypertension: Implications for Dynamin-Related Protein 1 and Mitofusin2 in Hyperproliferative Diseases,” Cells 12, no. 14 (2023): 1897.

[214] L. Rios, S. Pokhrel, S. J. Li, G. Heo, B. Haileselassie, and D. Mochly-Rosen, “Targeting an Allosteric Site in Dynamin-Related Protein 1 to Inhibit Fis1-Mediated Mitochondrial Dysfunction,” Nature Communications 14, no. 1 (2023): 4356.

[215] G. Yepuri, L. M. Ramirez, G. G. Theophall, et al., “DIAPH1-MFN2 Interaction Regulates Mitochondria-SR/ER Contact and Modulates Ischemic/Hypoxic Stress,” Nature Communications 14, no. 1 (2023): 6900.

[216] S. B. Nyenhuis, X. Wu, M. P. Strub, et al., “OPA1 Helical Structures Give Perspective to Mitochondrial Dysfunction,” Nature 620, no. 7976 (2023): 1109–1116.

[217] C. Li, Q. Liu, Q. Chang, et al., “Role of Mitochondrial Fusion Proteins MFN2 and OPA1 on Lung Cellular Senescence in Chronic Obstructive Pulmonary Disease,” Respiratory Research 24, no. 1 (2023): 319.

[218] Y. Fan, Z. Cheng, L. Mao, et al., “PINK1/TAX1BP1-Directed Mitophagy Attenuates Vascular Endothelial Injury Induced by Copper Oxide Nanoparticles,” Journal of Nanobiotechnology 20, no. 1 (2022): 149.

[219] A. Ciesielska, M. Matyjek, and K. Kwiatkowska, “TLR4 and CD14 Trafficking and Its Influence on LPS-Induced Pro-Inflammatory Signaling,” Cellular and Molecular Life Sciences 78, no. 4 (2021): 1233–1261.

[220] Y. L. Zhang, W. X. Zhang, J. Q. Yan, et al., “Chalcone Derivatives Ameliorate Lipopolysaccharide-Induced Acute Lung Injury and Inflammation by Targeting MD2,” Acta Pharmacologica Sinica 43, no. 1 (2022): 76–85.

[221] Y. W. Wang, Y. H. Wu, J. Z. Zhang, et al., “Ruscogenin Attenuates Particulate Matter-Induced Acute Lung Injury in Mice via Protecting Pulmonary Endothelial Barrier and Inhibiting TLR4 Signaling Pathway,” Acta Pharmacologica Sinica 42, no. 5 (2021): 726–734.

[222] Y. Li, J. Qian, Y. Mi, et al., “The Pyranocoumarin-Enriched Extract From the Leaves of Calophyllum Membranaceum Alleviates LPS-Induced Acute Lung Injury in Mice by Inhibiting the TLR4/MD2 Interaction,” Fitoterapia 186 (2025): 106796.

[223] J. Y. Dou, Y. N. Wu, C. Gao, et al., “Ginseng and Platycodon grandiflorum Ameliorated Pulmonary Fibrosis and Inflammation Targeting TLR4-P2X7r/NLRP3 Signaling Pathway,” Journal of Ethnopharmacology 348 (2025): 119913.

[224] X. Zeng, X. Liu, and H. Bao, “Sulforaphane Suppresses Lipopolysaccharide- and Pam3CysSerLys4-Mediated Inflammation in Chronic Obstructive Pulmonary Disease via Toll-Like Receptors,” FEBS Open Bio 11, no. 5 (2021): 1313–1321.

[225] E. E. West, T. Woodruff, V. Fremeaux-Bacchi, and C. Kemper, “Complement in Human Disease: Approved and Up-And-Coming Therapeutics,” Lancet 403, no. 10424 (2024): 392–405.

[226] Z. Yang, S. E. Nicholson, T. S. Cancio, L. C. Cancio, and Y. Li, “Complement as a Vital Nexus of the Pathobiological Connectome for Acute Respiratory Distress Syndrome: An Emerging Therapeutic Target,” Frontiers in Immunology 14 (2023): 1100461.

[227] A. P. J. Vlaar, M. Witzenrath, P. van Paassen, et al., “Anti-C5a Antibody (Vilobelimab) Therapy for Critically Ill, Invasively Mechanically Ventilated Patients With COVID-19 (PANAMO): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial,” Lancet Respiratory Medicine 10, no. 12 (2022): 1137–1146.

[228] L. Dai, Y. Chen, J. Wu, et al., “A Novel Complement C3 Inhibitor CP40-KK Protects Against Experimental Pulmonary Arterial Hypertension via an Inflammasome NLRP3 Associated Pathway,” Journal of Translational Medicine 22, no. 1 (2024): 164.

[229] C. Li, K. Patel, Z. Tu, et al., “A Novel Injury Site-Natural Antibody Targeted Complement Inhibitor Protects Against Lung Transplant Injury,” American Journal of Transplantation 21, no. 6 (2021): 2067–2078.

[230] E. Cerier, C. Kurihara, T. Kaiho, et al., “Temporal Correlation Between Postreperfusion Complement Deposition and Severe Primary Graft Dysfunction in Lung Allografts,” American Journal of Transplantation 24, no. 4 (2024): 577–590.

[231] N. Song, M. Scholtemeijer, and K. Shah, “Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential,” Trends in Pharmacological Sciences 41, no. 9 (2020): 653–664.

[232] Y. Huang, Q. Wu, and P. K. H. Tam, “Immunomodulatory Mechanisms of Mesenchymal Stem Cells and Their Potential Clinical Applications,” International Journal of Molecular Sciences 23, no. 17 (2022): 10023.

[233] H. Dunbar, D. J. Weiss, S. Rolandsson Enes, J. G. Laffey, and K. English, “The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing,” Cells 10, no. 11 (2021): 2982.

[234] D. F. Doherty, L. Roets, and A. D. Krasnodembskaya, “The Role of Lung Resident Mesenchymal Stromal Cells in the Pathogenesis and Repair of Chronic Lung Disease,” Stem Cells 41, no. 5 (2023): 431–443.

[235] E. Ferrini, F. F. Stellari, V. Franceschi, et al., “Persistency of Mesenchymal Stromal/Stem Cells in Lungs,” Frontiers in Cell and Development Biology 9 (2021): 709225.

[236] E. Cui, L. Lv, W. Chen, N. Chen, and R. Pan, “Mesenchymal Stem/Stromal Cell-Based Cell-Free Therapy for the Treatment of Acute Lung Injury,” Journal of Cellular Biochemistry 124, no. 9 (2023): 1241–1248.

[237] J. Liang, W. Dai, S. Xue, F. Wu, E. Cui, and R. Pan, “Recent Progress in Mesenchymal Stem Cell-Based Therapy for Acute Lung Injury,” Cell and Tissue Banking 25, no. 2 (2024): 677–684.

[238] L. Wang, Y. Tang, J. Tang, et al., “Endothelial Cell-Derived Extracellular Vesicles Expressing Surface VCAM1 Promote Sepsis-Related Acute Lung Injury by Targeting and Reprogramming Monocytes,” Journal of Extracellular Vesicles 13, no. 3 (2024): e12423.

[239] J. Zhang, X. Hu, T. Wang, et al., “Extracellular Vesicles in Venous Thromboembolism and Pulmonary Hypertension,” Journal of Nanobiotechnology 21, no. 1 (2023): 461.

[240] A. B. Česnik and U. Švajger, “The Issue of Heterogeneity of MSC-Based Advanced Therapy Medicinal Products-A Review,” Frontiers in Cell and Developmental Biology 12 (2024): 1400347.

[241] L. Liu, J. Fandiño, S. D. McCarthy, et al., “The Effects of the Pneumonia Lung Microenvironment on MSC Function,” Cells 13, no. 18 (2024): 1581.

[242] X. Xiao, M. Xu, H. Yu, et al., “Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Mitigate Oxidative Stress-Induced Senescence in Endothelial Cells via Regulation of miR-146a/Src,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 354.

[243] H. Shen, R. Zheng, M. Du, and D. C. Christiani, “Environmental Pollutants Exposure-Derived Extracellular Vesicles: Crucial Players in Respiratory Disorders,” Thorax 79, no. 7 (2024): 680–691.

[244] Y. Ma, X. Liu, Y. Long, and Y. Chen, “Emerging Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Chronic Respiratory Diseases: An Overview of Recent Progress,” Frontiers in Bioengineering and Biotechnology 10 (2022): 845042.

[245] X. Wu, Y. Tang, X. Lu, et al., “Endothelial Cell-Derived Extracellular Vesicles Modulate the Therapeutic Efficacy of Mesenchymal Stem Cells Through IDH2/TET Pathway in ARDS,” Cell Communication and Signaling: CCS 22, no. 1 (2024): 293.

[246] P. Rozier, M. Maumus, A. T. J. Maria, et al., “Lung Fibrosis Is Improved by Extracellular Vesicles From IFNγ-Primed Mesenchymal Stromal Cells in Murine Systemic Sclerosis,” Cells 10, no. 10 (2021): 2727.

[247] Y. Long, B. Yang, Q. Lei, et al., “Targeting Senescent Alveolar Epithelial Cells Using Engineered Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat Pulmonary Fibrosis,” ACS Nano 18, no. 9 (2024): 7046–7063.

[248] A. Jiang, N. Liu, J. Wang, et al., “The Role of PD-1/PD-L1 Axis in Idiopathic Pulmonary Fibrosis: Friend or Foe?,” Frontiers in Immunology 13 (2022): 1022228.

[249] T. Wakabayashi and H. Naito, “Cellular Heterogeneity and Stem Cells of Vascular Endothelial Cells in Blood Vessel Formation and Homeostasis: Insights From Single-Cell RNA Sequencing,” Frontiers in Cell and Developmental Biology 11 (2023): 1146399.

[250] Y. Li, Y.-N. Wang, Y.-G. Luo, H. Yang, J. Ren, and X. Li, “Advances in Synthetic Biology-Based Drug Delivery Systems for Disease Treatment,” Chinese Chemical Letters 35, no. 11 (2024): 109576.

[251] C. Y. Lin, Y. T. Chang, Y. K. Chung, A. Alalaiwe, H. P. Yu, and J. Y. Fang, “Dual-Membrane Bioinspired Nanocarriers for Targeted Therapy of MRSA-Induced Acute Lung Injury and Bacteremia,” Journal of Materials Chemistry B 13, no. 19 (2025): 5686–5704.

[252] W. Wang, Z. Zhong, Z. Huang, et al., “Nanomedicines for Targeted Pulmonary Delivery: Receptor-Mediated Strategy and Alternatives,” Nanoscale 16, no. 6 (2024): 2820–2833.

[253] S. Z. Alshawwa, A. A. Kassem, R. M. Farid, S. K. Mostafa, and G. S. Labib, “Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence,” Pharmaceutics 14, no. 4 (2022): 883.

[254] P. Kolb, C. Upagupta, M. Vierhout, et al., “The Importance of Interventional Timing in the Bleomycin Model of Pulmonary Fibrosis,” European Respiratory Journal 55, no. 6 (2020): 1901105.

[255] J. Rodor, S. H. Chen, J. P. Scanlon, et al., “Single-Cell RNA Sequencing Profiling of Mouse Endothelial Cells in Response to Pulmonary Arterial Hypertension,” Cardiovascular Research 118, no. 11 (2022): 2519–2534.

[256] S. Zong, P. Du, H. Li, M. Wang, and H. Xiao, “Advances in Animal Models of Obstructive Sleep Apnea,” Frontiers in Medicine 10 (2023): 988752.

[257] F. Alessandrini, S. Musiol, E. Schneider, F. Blanco-Pérez, and M. Albrecht, “Mimicking Antigen-Driven Asthma in Rodent Models-How Close Can we Get?,” Frontiers in Immunology 11 (2020): 575936.

[258] G. S. Gould, J. R. Hurst, A. Trofor, et al., “Recognising the Importance of Chronic Lung Disease: A Consensus Statement From the Global Alliance for Chronic Diseases (Lung Diseases Group),” Respiratory Research 24, no. 1 (2023): 15.

[259] I. Sayers, C. John, J. Chen, and I. P. Hall, “Genetics of Chronic Respiratory Disease,” Nature Reviews. Genetics 25, no. 8 (2024): 534–547.

[260] J. Zhang, Y. Guo, M. Mak, and Z. Tao, “Translational Medicine for Acute Lung Injury,” Journal of Translational Medicine 22, no. 1 (2024): 25.

[261] J. S. Woodrow, M. K. Sheats, B. Cooper, and R. Bayless, “Asthma: The Use of Animal Models and Their Translational Utility,” Cells 12, no. 7 (2023): 1091.

[262] G. O. Ramirez, C. A. Mariano, D. Carter, and M. Eskandari, “Visceral Pleura Mechanics: Characterization of Human, Pig, and Rat Lung Material Properties,” Acta Biomaterialia 189 (2024): 388–398.

[263] M. Arif, A. Basu, K. M. Wolf, et al., “An Integrative Multiomics Framework for Identification of Therapeutic Targets in Pulmonary Fibrosis,” Advancement of Science 10, no. 16 (2023): e2207454.

[264] J. Xie, Y. Hu, D. Sun, C. Liu, Z. Li, and J. Zhu, “Targeting Non-Coding RNA H19: A Potential Therapeutic Approach in Pulmonary Diseases,” Frontiers in Pharmacology 13 (2022): 978151.

[265] A. A. Faniyi, M. J. Hughes, A. Scott, K. B. R. Belchamber, and E. Sapey, “Inflammation, Ageing and Diseases of the Lung: Potential Therapeutic Strategies From Shared Biological Pathways,” British Journal of Pharmacology 179, no. 9 (2022): 1790–1807.

[266] R. Rajesh, R. Atallah, and T. Bärnthaler, “Dysregulation of Metabolic Pathways in Pulmonary Fibrosis,” Pharmacology & Therapeutics 246 (2023): 108436.

[267] W. Xu, A. J. Janocha, and S. C. Erzurum, “Metabolism in Pulmonary Hypertension,” Annual Review of Physiology 83 (2021): 551–576.

[268] D. Krentzel, S. L. Shorte, and C. Zimmer, “Deep Learning in Image-Based Phenotypic Drug Discovery,” Trends in Cell Biology 33, no. 7 (2023): 538–554.

[269] M. Pozzi, S. Noei, E. Robbi, et al., “Generating and Evaluating Synthetic Data in Digital Pathology Through Diffusion Models,” Scientific Reports 14, no. 1 (2024): 28435.

[270] X. Dong, C. Yang, Z. Ma, M. Chen, X. Zhang, and C. Bi, “Enhancing Glycosylase Base-Editor Activity by Fusion to Transactivation Modules,” Cell Reports 40, no. 3 (2022): 111090.

[271] R. S. Rosen, J. H. Yang, J. S. Peña, R. Schloss, and M. L. Yarmush, “An In Vitro Model of the Macrophage-Endothelial Interface to Characterize CAR T-Cell Induced Cytokine Storm,” Scientific Reports 13, no. 1 (2023): 18835.

[272] M. Zhong, G. M. Chalbatani, M. Deng, et al., “Functional Characterization and Development of Novel Human Kinase Insert Domain Receptor Chimeric Antigen Receptor T-Cells for Immunotherapy of Non-Small Cell Lung Cancer,” European Journal of Pharmaceutical Sciences 180 (2023): 106331.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.